National Center for Genome Medicine, Academia Sinica, Taipei, Taiwan.
J Gastroenterol. 2014 Aug;49(8):1274-84. doi: 10.1007/s00535-013-0890-2. Epub 2013 Oct 16.
It is known that malignant transformation to hepatocellular carcinoma (HCC) occurs at a higher frequency in hepatocellular adenoma (HCA) from type I glycogen storage disease (GSD I) compared to HCA from other etiologies. In this study, we aimed to identify differentially expressed miRNAs in GSD Ia HCA as candidates that could serve as putative biomarkers for detection of GSD Ia HCA and/or risk assessment of malignant transformation.
Utilizing massively parallel sequencing, the miRNA profiling was performed for paired adenomas and normal liver tissues from seven GSD Ia patients. Differentially expressed miRNAs were validated in liver tumor tissues, HCC cell lines and serum using quantitative RT-PCR.
miR-34a, miR-34a, miR-224, miR-224, miR-424, miR-452 and miR-455-5p were found to be commonly deregulated in GSD Ia HCA, general population HCA, and HCC cell lines at compatible levels. In comparison with GSD Ia HCA, the upregulation of miR-130b and downregulation of miR-199a-5p, miR-199b-5p, and miR-214 were more significant in HCC cell lines. Furthermore, serum level of miR-130b in GSD Ia patients with HCA was moderately higher than that in either GSD Ia patients without HCA or healthy individuals.
We make the first observation of distinct miRNA deregulation in HCA associated with GSD Ia. We also provide evidence that miR-130b could serve as a circulating biomarker for detection of GSD Ia HCA. This work provides prominent candidate miRNAs worth evaluating as biomarkers for monitoring the development and progress of liver tumors in GSD Ia patients in the future.
已知与其他病因相比,糖原贮积病 I 型(GSD I)肝腺瘤(HCA)发生肝细胞癌(HCC)恶变的频率更高。本研究旨在鉴定 GSD Ia HCA 中差异表达的 miRNA,作为可能的生物标志物,用于检测 GSD Ia HCA 和/或恶性转化的风险评估。
利用大规模平行测序,对 7 例 GSD Ia 患者的腺瘤和正常肝组织进行 miRNA 谱分析。采用定量 RT-PCR 在肝肿瘤组织、HCC 细胞系和血清中验证差异表达的 miRNA。
miR-34a、miR-34a、miR-224、miR-224、miR-424、miR-452 和 miR-455-5p 在 GSD Ia HCA、普通人群 HCA 和 HCC 细胞系中均普遍下调。与 GSD Ia HCA 相比,miR-130b 在 HCC 细胞系中上调更为显著,而 miR-199a-5p、miR-199b-5p 和 miR-214 下调更为显著。此外,GSD Ia 伴 HCA 患者血清 miR-130b 水平高于 GSD Ia 无 HCA 患者和健康个体。
我们首次观察到 GSD Ia 相关 HCA 中存在明显的 miRNA 失调。我们还提供了证据表明,miR-130b 可作为检测 GSD Ia HCA 的循环生物标志物。这项工作为未来监测 GSD Ia 患者肝脏肿瘤的发展和进展提供了值得评估的显著候选 miRNA 作为生物标志物。